Drug Discovery

Cognito Therapeutics and Ochsner partner for new brain health approaches

US-based neurotechnology company Cognito Therapeutics has collaborated with Ochsner Health to establish the Brain Health Collaboratory, aiming to advance new care models for cognitive decline and Alzheimer’s disease in the Gulf South.

Daiichi Sankyo and Tempus AI collaborate on ADC clinical development

Daiichi Sankyo has entered a strategic collaboration with Tempus AI to expedite the clinical development and differentiation of an antibody drug conjugate (ADC) programme in the field of oncology.

Viz.ai and Alnylam to advance earlier identification of cardiac amyloidosis

Viz.ai has entered a collaboration with Alnylam to advance earlier identification and streamline diagnosis for cardiac amyloidosis, an underdiagnosed cause of heart failure.

MSD and Quotient collaborate on IBD drug targets

Merck & Co (MSD) has signed a multi-year research collaboration with Quotient Therapeutics to discover new drug targets for inflammatory bowel disease (IBD) using the latter’s somatic genomics platform technology.

Monash University and ClinChoice partner on new therapies development

Australia-based Monash University and ClinChoice have announced a strategic partnership to accelerate clinical development of new therapies.

Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody

Sanofi has signed an exclusive global licence agreement with Kali Therapeutics for KT501, a new tri-specific antibody for B cell-mediated autoimmune diseases.

ImmunityBio receives Macau approval for Anktiva combo therapy

ImmunityBio has received approval from the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region, China, for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for bladder cancer.

Novartis to acquire SNV4818 from Synnovation

Novartis has signed an agreement to acquire SNV4818, a pan-mutant selective Phosphoinositide 3-kinase alpha (PI3Kα) inhibitor, from Synnovation Therapeutics.

Congruence secures $39.5m to advance small molecule correctors pipeline

Congruence Therapeutics has announced the completion of a $39.5m financing round to advance its portfolio of small molecule correctors into the clinic.